Stock converts smartphone cameras into a clinical grade medical device.

Sign up today and learn more about Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Stock is a pioneer in turning the smartphone camera into a clinical grade medical device. Founded in 2013 by founder and CEO, Yonatan Adiri, it took us only three years to reach from idea to global revenues through successful clinical trials. Our first product,, is the world’s first clinically approved home urinalysis kit. The product effectively turns the smartphone into a clinical grade urinalysis device, enabling the layperson to conduct clinically required urine testing with a simple smartphone scan. was followed by ACR - a second urinalysis test that lets people with diabetes or high blood pressure reliably test themselves at home for kidney disease. The product achieved 99% usability success and is being rolled out for large population screening in Europe, using digital technology to change the dynamics of chronic kidney disease prevention. Our second product family - Chronic wound monitoring - is an assessment tool to analyze chronic wounds over time and facilitate better care coordination.


Joy Capital

La Maison Compagnie d'Investissement

fabric,, Taboola

Funding History

August 2014$3.0M
August 2017$14.0M
February 2019$18.2M
April 2019$50.0M


Vice-President of Strategy

Joel Schoppig

Chief Product Officer

Ron Zohar

Chief Commercial Officer, Managing Director UK & Europe

Katherine Ward

Founder, CEO

Jonathan (Yonatan) Adiri

Vice-President of Research and Development

Eitan Gur

Chief Scientist

Dr. Ido Omer

CFO and President of North America.

Heather Getz

Product Manager

Nitzan Mayer-Wolf

Board Of Directors

Daniel Kraft


Gary Loveman


Oz Shohat


Shachar Mendelowitz


Yoav Sebba

Board Member

Michael Eisenberg


vimeo - May, 3 2017 on BBC World News

vimeo - May, 3 2017 on CNBC Squawkbox

bloombergview - May, 3 2017

China's Leap Forward in Digital Medicine

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: